Sandoz is a global pharmaceutical manufacturer focused on generic medicines and biosimilars. The company is a leading producer of anti-infectives—particularly penicillins—and supplies active pharmaceutical ingredients (APIs) and finished-dose formulations to healthcare systems worldwide. Its operations span chemical synthesis, industrial fermentation, and biopharmaceutical manufacturing, with a strong presence in Europe.
Sandoz maintains a vertically integrated penicillin network in Europe and invests in advanced capabilities for biosimilar development and analytical characterization. Key sites include antibiotics production in Kundl, Austria; biosimilar R&D in Holzkirchen, Germany; and expanding biologics and bioproduction activities in Slovenia. The company emphasizes secure, regional supply chains for critical medicines and manufactures to international GMP and quality standards, making it a significant player at the intersection of the chemical and life sciences industries.
chemXplore tracks 3 projects involving Sandoz, of which one is active.
Sandoz's role on them: Owner, Operator, and Developer.
1 new construction.
Takes office May 1, 2026. Jany has 30+ years in finance, 20 years as CFO in listed firms; formerly EVP & CFO at A.P. Moller–Maersk and Group CFO at Clariant. Interim CFO Daniel Turnheim stays until then
A chemical leak caused an odor, prompting residents to stay indoors. No injuries or contamination occurred. The cause is under investigation, and safety protocols were effective.
EUR 175M investment enhances penicillin production and biosimilar development, improving ecological footprint and securing European supply. Supported by Austrian and Bavarian governments.
The $400M investment aims to boost biosimilar production, with operations starting in 2026. This supports the company's growth in biosimilars and antibiotics, enhancing access to critical medicines.
The spin-off aims to create a leading European generics and global biosimilars company, enhancing focus and growth for both entities, with completion expected in H2 2023, subject to approvals.
